Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.
Details
News Market Reaction – CDXS
On Feb 25, the day this news came out, CDXS closed 1.36% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Earnings release date
- March 11, 2026
- Fourth quarter and fiscal year 2025 financial results
- Earnings release time
- After market close
- Q4 and FY 2025 financial results timing
- Conference call time
- 4:30 pm Eastern Time
- Management call to discuss Q4 and FY 2025 results
- Webcast archive duration
- 90 days
- Investor Relations website earnings call replay period
- Telephone replay duration
- 48 hours
- Availability of telephone replay of the earnings call
- Domestic dial-in
- 877-705-2976
- US access number for live earnings conference call
- International dial-in
- 201-689-8798
- International access number for live earnings conference call
- Replay access ID
- 13726635
- Access ID for telephone replay of earnings call
Historical Context
-
Announcement of TD Cowen healthcare conference fireside chat and webcast access.
-
ISO 9001:2015 certification for core facilities and quality management systems.
-
Axolabs evaluation agreement for ECO Synthesis oligonucleotide manufacturing platform.
-
Signing of lease for 34,000 sq ft GMP facility to expand production capacity.
-
Q3 2025 results with revenue decline, restructuring, and extended cash runway through 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.